eli lilly glp-1 advantage decreasing orforglipron oral phase 3 weight loss trial Eli Lilly's New $299 Month-Long
Description

doi: 10.1210/jc.2010-1642 30 KlingensmithGJConnorCGRuedyKJBeckRWKollmanCHaroHet al

Diabetologia (2016) 59(5):105969

Analyzing the FDA Adverse Event Reporting System showed sitagliptin to be the drug reported to cause the most hypoglycemia, whereas the hypoglycemic potential of the meglitinides (short-acting sulfonylurea analogs) was not picked up as significant and the hypoglycemic potential of sulfonylureas and even of insulin was greatly underestimated when these results are compared with well-known epidemiological data (Supplementary Fig
While there is no established direct effect of semaglutide on salivary gland function through its GLP-1 receptor mechanism, several indirect pathways may explain why some patients report dry mouth during treatment

Over time, especially with regular or repetitive vomiting, stomach acids can weaken your teeth, making problems like erosion or decay more likely
